Kalluri Anita L, Lee Joyce H, Lucas Calixto-Hope G, Rincon-Torroella Jordina, Bettegowda Chetan
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Neurooncol. 2025 Feb;171(3):559-569. doi: 10.1007/s11060-024-04883-0. Epub 2024 Nov 12.
The incorporation of molecular markers into neuro-oncology has transformed our understanding of adult diffuse gliomas. While surgical resection is the mainstay of treatment for many patients with gliomas, surgical management strategies warrant re-exploration in the context of characteristic molecular profiles.
We reviewed the neurosurgical and neuro-oncological literature for studies investigating surgery in molecularly defined cohorts of adult diffuse gliomas.
We discuss key molecular markers associated with the three subtypes of adult diffuse glioma: glioblastoma IDH-wildtype, astrocytoma IDH-mutant, and oligodendroglioma IDH-mutant and 1p/19q codeleted. We additionally discuss surgical strategies and extent of resection in these tumors, framing them in the context of key molecular alterations. Finally, we briefly discuss the practical utility of molecular markers in guiding surgical decision making.
Molecular markers in gliomas are of growing relevance to surgical intervention. Advancements in preoperative and intraoperative molecular diagnostics will increase the utility of molecular biomarkers in informing surgical decision-making for patients with gliomas.
将分子标志物纳入神经肿瘤学已改变了我们对成人弥漫性胶质瘤的认识。虽然手术切除是许多胶质瘤患者的主要治疗方法,但在具有特征性分子特征的背景下,手术管理策略值得重新探索。
我们查阅了神经外科和神经肿瘤学文献,以研究分子定义的成人弥漫性胶质瘤队列中的手术情况。
我们讨论了与成人弥漫性胶质瘤的三种亚型相关的关键分子标志物:胶质母细胞瘤异柠檬酸脱氢酶(IDH)野生型、星形细胞瘤IDH突变型以及少突胶质细胞瘤IDH突变型且1p/19q共缺失型。我们还讨论了这些肿瘤的手术策略和切除范围,并将其置于关键分子改变的背景下。最后,我们简要讨论了分子标志物在指导手术决策中的实际应用。
胶质瘤中的分子标志物与手术干预的相关性日益增加。术前和术中分子诊断的进展将提高分子生物标志物在为胶质瘤患者提供手术决策信息方面的效用。